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Abstract
Aims/hypothesis To assess the effect of an angiotensin
receptor blocker (ARB) on serum potassium and the effect
of a serum potassium change on renal outcomes in patients
with type 2 diabetes and nephropathy.
Methods We performed a post hoc analysis in patients with
type 2 diabetes participating in the Reduction of Endpoints in
NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) study. Renal outcomes were defined as a compos-
ite of doubling of serum creatinine or end-stage renal disease.
Results At month 6, 259 (38.4%) and 73 (10.8%) patients
in the losartan group and 151 (22.8%) and 34 (5.1%) patients
in the placebo group had serum potassium ≥5.0 mmol/l and
≥5.5 mmol/l, (p<0.001), respectively. Losartan was an
independent predictor for serum potassium ≥5.0 mmol/l at
month 6 (OR 2.8; 95% CI 2.0–3.9). Serum potassium at
month 6 ≥ 5.0 mmol/l was in turn associated with increased
risk for renal events (HR 1.22; 95% CI 1.00–1.50),
independent of other risk factors. Adjustment of the overall
treatment effects for serum potassium augmented losartan’s
renoprotective effect from 21% (6–34%) to 35% (20–48%),
suggesting that the renoprotective effects of losartan are
offset by its effect on serum potassium.
Conclusions/interpretation In this study, we found that
treatment with the ARB losartan is associated with a high
risk of increased serum potassium levels, which is in turn
associated with an increased risk of renal outcomes in
patients with diabetes and nephropathy. Whether additional
management of high serum potassium would further
increase the renal protective properties of losartan is an
important clinical question.
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Introduction
Diabetic nephropathy is the leading cause of end-stage renal
disease (ESRD) in western societies. As the prevalence of
diabetes is increasing, ESRD accounts for substantial
morbidity and mortality [1, 2].
Angiotensin receptor blockers (ARBs) have several
important beneficial effects in patients with diabetes and
nephropathy, such as decreasing systemic blood pressure
and reducing albuminuria. These effects are related to long-
term renal protection [3, 4]. However, these beneficial
effects are accompanied by a so-called side effect of ARBs,
induction of a rise in serum potassium levels even leading
to hyperkalaemia. This situation may in turn lead to
detrimental long-term effects [5]. The risk of hyperkalaemia
is particularly high in patients with diabetes as these
patients already have reduced aldosterone production
secondary to renin deficiency, the so-called hyporeninemic
hypoaldosteronism syndrome [6, 7]. Diabetes, low renal
function and use of renin–angiotensin–aldosterone system
(RAAS) inhibitors are independent factors that increase
serum potassium level. In combination, these factors pose
patients at even higher risk of hyperkalaemia [8].
Increased serum potassium levels are associated with
increased risk for cardiovascular (CV) morbidity and
mortality. Hyperkalaemia as a result of ARB therapy has
been related to worse CV outcomes [9]. However, the
relationship between change in serum potassium levels in
response to RAAS therapy and renal outcomes is not well
established. Therefore, we assessed the relationship be-
tween ARB treatment, serum potassium levels and renal
outcomes in patients with type 2 diabetes and nephropathy
participating in the Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan (RENAAL) trial
(Clinical trials.gov identifier: NCT 00308347).
Methods
Study design The RENAAL trial was a multinational,
randomised, double-blind trial that compared the effects of
losartan vs placebo in addition to conventional anti-
hypertensive medication in patients with type 2 diabetes
and nephropathy. Patients had serum creatinine levels
between 115 and 265 μmol/l (133 to 265 μmol/l for men
weighing more than 60 kg). The study was performed in
250 centres in 28 countries and involved 1,513 patients.
The study design, the inclusion/exclusion criteria, and the
treatment protocol have been reported previously [3, 10]. In
short, after a 6-week screening phase, patients were
randomised to either losartan 50 mg (titrated to 100 mg
after 4 weeks) or placebo. Additional antihypertensive
medications (calcium channel blockers, β-blockers, centrally
acting agents, and diuretics, excluding angiotensin-
converting enzyme inhibitors or other angiotensin receptor
antagonists) were permitted to reach the blood pressure goal
of <140/90 mmHg (systolic/diastolic). All patients signed
informedconsentbeforeenrolment,andthelocalInstitutional
Review Board of each participating centre approved the
study. The mean duration of follow-up was 3.4 years. Blood
pressure, serum potassium level, serum creatinine and
albumin:creatinine ratio were measured at first month, third
month, and then every 3 months until the end of the study.
Change in serum potassium and outcomes In this study, we
performed a post hoc analysis of all individuals with
potassium measurements included in the RENAAL trial.
We assessed the relationship between serum potassium
level and renal outcomes in two ways. First, we assessed
the relationship between serum potassium and renal out-
comes at month 6. The month 6 values were chosen as the
treatment effects were considered to be fully present and
relatively few renal events occurred before month 6. The
month 6 serum potassium level was classified into two
categories: <5.0 mmol/l (reference, and ≥5.0 mmol/l [11].
We selected this threshold (instead of the clinical accepted
value of 5.5 mmol/l) because the risk of adverse renal
outcomes started to increase from 5.0 mmol/l, and a small
number of patients reached serum potassium levels
≥5.5 mmol/l in our population. As a single elevated
potassium measurement may be an erroneous finding, we
also assessed the relationship between persistent drug-
induced serum potassium at months 6 and 9 and its
association with renal outcome. These individuals were
either compared with those with a single elevated serum
potassium measurement at month 6 or 9, or compared with
those without increases in serum potassium above
5.0 mmol/l during the first 9 months of follow-up.
In the second approach, we calculated the average serum
potassium concentration during follow-up and explored the
relationship between the average serum potassium level
during follow-up with renal outcomes. The average serum
potassium concentration, as well as average levels of other
relevant covariates was calculated as the mean of the first
month and each consecutive third month potassium value
until the occurrence of the renal event. This approach was
chosen as it more accurately reflects the risk of a participant
to exposure to a high serum potassium load for a definite
period of time than a single elevated measure. Renal out-
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creatinine (DSCR) or ESRD, and as DSCR and ESRD
individually. All endpoints were adjudicated by a blinded
endpoint committee using rigorous guideline definitions.
Statistical analysis Differences among patient subgroups
were evaluated by using chi-squared test or t test, as
appropriate. Mean serum potassium level at each visit
during follow-up, as well as the proportion of patients with
month 6 potassium level ≥5.0 mmol/l and ≥5.5 mmol/l was
calculated in both the losartan and placebo group. To
identify the predictors of increased serum potassium at
month 6, a multivariate logistic regression model was used.
Baseline characteristics that showed an association with
serum potassium ≥5.0 mmol/l (p<0.2) at univariate analysis
were selected for the multivariate logistic model. The
multivariate logistic model was adjusted for age, treatment
assignment, serum potassium, diastolic blood pressure,
estimated glomerular filtration rate (eGFR), month 6
change in eGFR from baseline, urinary albumin:creatinine
ratio (ACR), prescription of α-blockers, thiazide diuretics,
loop diuretics, and haemoglobin. To assess the association
between change in serum potassium from baseline to
month 6 and renal outcomes, a multivariate Cox proportional
hazard model was used. The linearity of baseline and follow-
up continuous variables was assessed. If the linearity was not
demonstrated, the variable was recoded as a categorical
variable. In the final Cox model we adjusted for the following
baseline variables: age, sex, race, treatment, eGFR, follow-up
systolic blood pressure, diastolic blood pressure, ACR. We
checked for an interaction between serum potassium levels at
month 6 and eGFR. To ensure that our results are not affected
by baseline renal function and other important predictors of
renal outcomes, such as blood pressure and urinary albumin
excretion we performed a sensitivity analysis in which we
matchedpatientsbasedontheirpropensityscoreofdeveloping
serum potassium ≥5.0 mmol/l. The propensity score was
obtained by performing a logistic regression model with serum
potassium ≥5.0 mmol/l as an outcome. The risk of renal
outcomes was presented by hazard ratios (HR) with 95%
confidence intervals (95% CI). Analyses were conducted with
SPSS version 16.0 software.
Results
Serum potassium over time and characteristics of the study
population In the whole population at month 6, 928
(69.4%) patients had a serum potassium <5.0 mmol/
l (normal value) while 410 (30.6%) patients had month 6
serum potassium ≥5.0 mmol/l (Table 1). In the losartan
group, mean potassium level significantly increased from
4.59 mmol/l at baseline to 4.79 mmol/l at month 6, and
remained relatively stable during follow-up (Fig. 1). In
contrast, in the placebo group, the mean potassium level
decreased gradually from 4.62 mmol/l at baseline to
4.56 mmol/l at month 6, and remained relatively stable
thereafter.
The percentage of patients with month 6 serum potassium
levels ≥5.0 mmol/l and ≥5.5 mmol/l increased from 167
(22.2%) at baseline to 259 (38.4%) and 22 (2.9%) at baseline
to 73 (10.8%) at month 6, respectively in patients on losartan,
while in those on placebo it decreased from 200 (26.2%) to
Table 1 Baseline and month 6 characteristics of the whole population
a
Serum potassium at month 6 (mmol/l)
Baseline characteristic <5.0 (n=928) ≥5.0 mmol/l (n=410)
Age ( years) 60.0 (7.6) 60.4 (7.1)
Male, n (%) 593 (63.9) 248 (60.5)
Race, n (%)
White 449 (48.4) 198 (48.3)
†
Black 161 (17.3) 40 (9.8)
Hispanic 144 (15.5) 98 (23.9)
Asian 163 (17.6) 68 (16.6)
Other 11 (1.2) 6 (1.5)
Systolic BP (mmHg) 152.1 (19.2) 153.2 (19.7)
Diastolic BP (mmHg) 82.9 (10.5) 81.3 (10.1)
b
Urinary ACR (mg/mmol),
median (IQR)
129 (59–263) 155 (76–327)
b
Serum creatinine (μmol/l) 161 (41.6) 173 (42.9)
b
eGFR (mlmin
–1 1.73 m
–2) 40.9 (12.2) 37.0 (11.9)
b
HbA1c, (%) 8.4 (1.6) 8.4 (1.6)
Haemoglobin (g/l) 127 (18) 121 (18)
b
Serum potassium (mmol/l) 4.5 (0.5) 4.9 (0.4)
b
Serum potassium ≥5.0
mmol/l, n (%)
140 (15.1) 187 (45.6)
b
Treatment, n (%)
Losartan 416 (44.8) 259 (63.2)
b
Thiazide diuretics 161 (17.3) 45 (11.0)
b
K-sparing diuretics 24 (2.6) 7 (1.7)
Loop diuretics 426 (45.9) 177 (43.2)
Calcium channel blocker 679 (73.2) 291 (71.0)
α-Blockers 239 (25.8) 81 (19.8)
b
β-Blockers 173 (18.6) 76 (18.5)
Month 6 characteristics
Systolic BP (mmHg) 149.3 (19.8) 150.1 (20.4)
Diastolic BP (mmHg) 81.2 (10.7) 79.3 (10.4)
b
Urinary ACR (mg/mmol),
median (IQR)
1095 (407-22-5) 1228 (454-2571)
b
eGFR (mlmin
–1 1.73 m
–2) 38.1 (14.2) 32.9 (13.2)
b
aData are presented as means (SD) unless otherwise indicated.
bp<0.05 between patients with K ≥5.0 mmol/l and those with K
<5.0 mmol/l at month 6.
BP, blood pressure; IQR, interquartile range
46 Diabetologia (2011) 54:44–50151 (22.8%) and from 35 (4.6%) to 34 (5.1%), respectively
(Fig. 2a, b).
Patients with serum potassium levels ≥5.0 mmol/l at
month 6 were more likely to have higher baseline serum
potassium levels, higher ACR, lower diastolic blood
pressure and lower haemoglobin levels compared with
patients with serum potassium <5.0 mmol/l (Table 1). The
use of losartan was more common, while the use of thiazide
diuretics and α-blockers was less common in patients with
serum potassium ≥5.0 mmol/l.
Predictors of incident serum potassium ≥5.0 mmol/l at
month 6 In testing in multivariate analysis which baseline
variables are related to increased serum potassium
≥5.0 mmol/l at month 6, we found that the strongest
baseline predictors were losartan therapy (OR 2.81; 95% CI
2.03–3.89) and serum potassium (OR 2.26; 95% 1.51–
3.37). In contrast, a decreased eGFR was associated with an
increased risk of high serum potassium (Table 2).
Month 6 serum potassium and renal outcomes Serum
potassium level was associated with a higher risk of the
composite renal outcome of DSCR or ESRD. As observed
in Fig. 3a, the risk already started to significantly increase
from serum potassium ≥5.0 mmol/l and further increased at
serum potassium ≥5.5 mmol/l during follow-up (HR 1.39;
95% CI 1.07–1.80 and HR 1.77; 95% CI 1.22–2.56,
respectively). However several other factors also explained
the progressive loss of renal function such as age, eGFR,
and ACR. The most important question was therefore
whether the progressive nature of renal endpoints in
patients with serum potassium ≥5.0 mmol/l is independent
of other factors, and most importantly, by the prevailing
renal function, as patients with low eGFR are more prone to
develop high serum potassium levels. After adjustment for
other risk factors, month 6 serum potassium ≥5.0 mmol/l
was associated with a 22% increased risk for developing
adverse renal outcomes (HR 1.22; 95% CI 1.00–1.50).
Further analysis revealed that this increased risk was merely
attributed to patients with persistent drug-induced serum
potassium ≥5.0 mmol/l both at month 6 and month 9 (HR
1.56; 95% CI 1.09–2.21) (Table 3).
In the second approach we assessed the association
between the mean serum potassium level during follow-up
with renal outcomes. The relationship between the mean
serum potassium level during follow-up displayed a similar
pattern with renal outcomes as the month 6 serum
potassium level (Fig. 3b). After controlling for potential
confounders, the analyses revealed that patients who
achieved a mean serum potassium ≥5.0 mmol/l during
follow-up had a 43% higher risk of the composite endpoint
of DSCR or ESRD (HR 1.36; 95% CI 1.11–1.67).
The sensitivity analysis in 712 patients matched per
propensity score showed similar detrimental effects of
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Fig. 2 Proportion of patients with serum potassium ≥5.0 mmol/l (a)
and ≥5.5 mmol/l (b) at baseline (black bars) and month 6 (white bars)
among patients assigned to losartan and placebo
Table 2 Baseline multivariate predictors of incident drug induced
serum potassium ≥5.0 mmol/l at month 6
Risk marker OR (95% CI) χ
2 p value
Losartan treatment 2.80 (2.02–3.88) 38.3 <0.001
Serum potassium (mmol/l) 2.30 (1.53–3.44) 26.2 <0.001
eGFR, (mlmin
–1 1.73 m
–2) 0.98 (0.97–0.99) 6.2 0.013
α-Blocker use 0.68 (0.46–1.01) 3.6 0.058
Loop diuretic use 0.75 (0.53–1.04) 3.0 0.085
Month 6 change eGFR
(mlmin
–1 1.73 m
–2)
1.02 (0.99–1.05) 2.9 0.086
Age (years) 1.02 (0.99–1.04) 2.2 0.141
Haemoglobin (g/l) 0.94 (0.85–1.04) 1.5 0.228
Diastolic blood pressure
(mmHg)
0.99 (0.98–1.01) 1.3 0.252
Log-transformed ACR,
log unit mg/mmol
1.06 (0.89–1.26) 0.4 0.541
Thiazide use 0.82 (0.53–1.27) 0.8 0.372
Predictors are ordered by decreasing significance based on χ
2values
Presented risk markers were selected for multivariate analysis if an
association with serum potassium ≥5.0 mmol/l was demonstrated in
univariate analyses. Risk markers are ordered according the χ
2values
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(HR 1.32; 1.03–1.70). There was no heterogeneity between
increased serum potassium and eGFR (p=0.132).
Effect of serum potassium ≥5.0 mmol/l on the renoprotection
induced by losartan To examine to what extent the increase
in potassium influences the renoprotective effect afforded
by losartan, we analysed the impact of an increase in serum
potassium on the losartan treatment effect. When the
treatment effect on losartan was adjusted for the residual
potassium level (last potassium level measured prior to the
renal endpoint), the treatment effect of losartan on the
DSCR or ESRD endpoint increased from 21% (6–34%) to
35% (20–48%). This finding suggests that the effect of
losartan on serum potassium offsets the renoprotective
effect of losartan.
Discussion
In this study, we showed that treatment with losartan
increased the serum potassium concentration. We further-
more demonstrated that the occurrence of high serum
potassium levels increased the risk of adverse renal outcomes
and counteract the beneficial renoprotective effects of
losartan. The increase in the renal risk appeared to be
independent of other important renal risk factors, such as
blood pressure, eGFR and ACR. Thus, although the
RENAAL trial has clearly shown that losartan is a renopro-
tective drug, under this protection a renal damaging effect is
hiding in those individuals in whom losartan induces high
serum potassium levels.
The effects of the ARB losartan on serum potassium are
in line with other studies. In patients with diabetes, either
addition or administration of an ARB increases the
incidence of hyperkalaemia, independent of renal function
[8]. Also, in patients with heart failure, addition of an ARB
or aldosterone antagonist to baseline RAAS inhibitor
therapy increases the risk of hyperkalaemia [9, 12]. In
contrast, in non-diabetic patients addition of RAAS-
inhibitors poses a minimal risk of hyperkalaemia as long
as renal function is relatively preserved [13–17]. It appears
that the risk of hyperkalaemia is particularly elevated in
patients with underlying predisposing disorders, such as
diabetes and renal insufficiency, and in patients who receive
combined RAAS therapy.
The mechanism via which ARB treatment induces
elevations in serum potassium levels has already been
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Table 3 Persistent and single elevated serum potassium ≥5.0 mmol/l
and their association with the risk for DSCR or ESRD
a
Risk factors HR (95% CI) χ
2 p value
Drug induced persistent
b serum
potassium ≥5.0 mmol/l
(month 6 and 9)
1.54 (1.07–2.22) 5.4 0.020
Single
c elevated serum potassium
≥5.0 mmol/l (month 6 or 9)
1.26 (0.93–1.70) 2.2 0.142
Age 0.97 (0.96–1.00) 2.3 0.126
Race (reference: White) –– –
Black 2.13 (146–3.10) 15.6 <0.001
Asian 1.42 (1.01–1.99) 4.0 0.046
Other 1.62 (1.18–2.21) 9.0 0.003
eGFR 0.96 (0.95–0.97) 46.6 <0.001
Systolic blood pressure 1.01 (1.00–1.02) 7.2 0.008
Diastolic blood pressure 0.99(0.98–1.01) 1.4 0.233
ACR 3.75 (3.12–4.51) 196.8 <0.001
Treatment (losartan/placebo)
d 0.92 (0.71–1.20) 0.4 0.538
aEssentially similar results were obtained for the individual compo-
nents of the endpoint (data not shown)
bPersistent elevated serum potassium defined as drug induced serum
potassium ≥5.0 mmol/l at month 6 and 9
cSingle elevated measurement defined as serum potassium ≥5.0 mmol/l
at month 6 or 9
dThere was no interaction between treatment groups and high
potassium at month 6 and 9 (p=0.284) indicating that the association
between high potassium and renal outcome are consistent across both
treatment groups
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regulated by serum aldosterone and sodium delivery to
the distal nephron. Blocking the effects of angiotensin II by
RAAS inhibitors decreases aldosterone production and
consequently induces hyperkalaemia. Patients with diabetes
are particularly susceptible to the hyperkalaemic effects of
RAAS inhibitors as their RAAS activity is already sup-
pressed. Several factors may account for this, such as an
impaired conversion of pro-renin to renin [18] or volume
expansion with subsequent increase in circulating atrial
natriuretic peptide levels and suppression of plasma renin
activity [19].
In previous studies no data are available on the effect of
high serum potassium levels on renal outcomes. Our study
showed for the first time that increased serum potassium
concentrations ≥5.0 mmol/l is associated with a clearly
increased risk of DSCR or ESRD, independent of renal
function and other important predictors of renal outcomes.
The pathophysiological mechanism whereby increased
serum potassium levels affect renal outcomes is not well
known. It is likely that individuals with persistent drug
induced hyperkalaemia are resistant against the kaliuretic
effects of aldosterone. It has indeed been shown that the
trans-tubular potassium gradient, as measure for aldosterone
bioactivity with respect to its kaliuretic response, is
decreased in individuals with drug induced hyperkalaemia
despite increased plasma aldosterone levels [20]. Conse-
quently, these individuals are continuously exposed to the
deleterious effects of aldosterone on renal tissue. Another
potential mechanism could be that a vicious cycle exits
between renal function and potassium levels that usually
takes place in disorders that affect both tubular dysfunction
and release of renin. On the one hand, a decrease in renal
perfusion and the start of tubulointerstitial damage may
impair renal potassium excretion, even though renal
function is only mildly depressed. This situation may lead
to an imbalance in renal potassium/sodium handling that
may further damage the tubules, thereby subsequently
contributing to a further decline in renal function [7].
Several reports have drawn attention to spurious hyper-
kalaemia (pseudohyperkalaemia) as a common problem in
clinical care [21, 22]. The reasons for spurious hyper-
kalaemia are multiple, such as inappropriate phlebotomy
technique (e.g. requesting patient to fist clench to facilitate
venesection), improper sample storage (i.e. cold storage or
too long storage causing deterioration of the sample speci-
men) or contamination with anticoagulant from another
sample (ethylene diamine tetra-acetic acid [EDTA]contami-
nation) [21, 22]. As it is unlikely that individuals with a
single erroneous potassium measurement are at increased
risk, we classified patients in those who had persistent high
serum potassium levels at month 6 and 9. As expected, the
increased risk for renal outcomes was particularly marked in
individuals with high serum potassium at both visit 6 and 9.
This implies that elevation in serum potassium level needs
particular attention and appropriate management if it is
confirmed at a follow-up visit. In addition, our data on the
relationship between the mean potassium level during
follow-up, which reflects the exposure to a high serum
potassium load during a definitive period of time more
accurately than a single value, and renal outcomes displayed
a similar association between increased serum potassium and
adverse renal outcomes. These results are in clear contrast to
a recent report from Weir et al. who suggested that the
changes in serum potassium concentration observed during
RAAS therapy are unlikely to be clinically significant [23].
We recommend not down-playing modest changes in serum
potassium as they independently indicate increased risk for
renal outcomes in the long-term.
Hyperkalaemia is usually defined by a serum potassium
concentration ≥5.5 mmol/l. Our results demonstrated a
distinct risk of adverse renal events in not only patients
with serum potassium concentration ≥5.5 mmol/l, but also
in patients with potassium concentrations ≥5.0 mmol/l
duringfollow-upandatmonth6.Theseresultshaveimportant
consequencesfor clinicalpractice asthey indicatethatthe risk
forrenaleventsalreadystartstoincreasewithinrangesthatare
currentlyconsideredtobenormal.Particularcautionisneeded
whenprescribinga secondRAASagent asthe combinationof
RAAS inhibitors may lead to even higher serum potassium
levels [24, 25]. In patients with high potassium levels at start
of ARB therapy, it may be initiated with a low dose, and
increased to a higher dose if serum potassium levels do not
increase above a therapeutic threshold.
Would improved management of high serum potassium
levels lead to better renal outcomes associated with RAAS
blockade? Our study does not directly answer this question.
However, when we adjusted the treatment effects by the
residual serum potassium levels measured prior to the renal
endpoint the renoprotective effects associated with losartan
use markedly improved. It is therefore tempting to
speculate that management of high serum potassium levels
improves the renoprotective effects of losartan. Further
prospective randomised controlled trials are needed to
confirm this finding.
Our study has some limitations. First, this is a post-hoc
analysis, and as such may be subject to confounding. To
control for confounding we adjusted for a wide range of
clinical variables, both at baseline and follow-up. It is
nevertheless possible that residual confounding remained
even in our multivariate adjusted analysis. Also, we
performed two additional sensitivity analyses matching
patients on their eGFR and propensity score to ensure that
renal events are independent of important predictors of
increased serum potassium. Second, although the RENAAL
trial included a broad range of patients with type 2 diabetes
Diabetologia (2011) 54:44–50 49and nephropathy, the findings cannot be extrapolated to
other populations.
In conclusion, in this study we found that treatment with
the ARB losartan is associated with a high risk of serum
potassium level elevation in patients with type 2 diabetes
and nephropathy. This elevated serum potassium level is in
turn associated with an increased risk of renal outcomes and
offsets the renoprotective effects of losartan. Whether
additional management of elevated serum potassium would
further increase the renal protective properties of losartan is
an important clinical question.
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